UNICA IRIS Institutional Research Information System

DEMELIA, LUIGI
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 103.640
NA - Nord America 4.560
AS - Asia 684
AF - Africa 9
SA - Sud America 4
Continente sconosciuto - Info sul continente non disponibili 3
Totale 108.900
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 102.160
US - Stati Uniti d'America 4.541
UA - Ucraina 542
CN - Cina 521
SE - Svezia 286
DE - Germania 274
FI - Finlandia 145
GB - Regno Unito 128
SG - Singapore 121
FR - Francia 41
RU - Federazione Russa 29
CA - Canada 18
VN - Vietnam 16
BE - Belgio 13
KR - Corea 5
DK - Danimarca 4
IN - India 4
NL - Olanda 4
PK - Pakistan 4
EU - Europa 3
MA - Marocco 3
BR - Brasile 2
CZ - Repubblica Ceca 2
ES - Italia 2
GE - Georgia 2
IL - Israele 2
MU - Mauritius 2
NG - Nigeria 2
PL - Polonia 2
AT - Austria 1
CH - Svizzera 1
CL - Cile 1
EG - Egitto 1
HK - Hong Kong 1
ID - Indonesia 1
IE - Irlanda 1
IR - Iran 1
JP - Giappone 1
LB - Libano 1
LU - Lussemburgo 1
MN - Mongolia 1
MY - Malesia 1
NO - Norvegia 1
PA - Panama 1
PE - Perù 1
PT - Portogallo 1
RO - Romania 1
SD - Sudan 1
SI - Slovenia 1
TR - Turchia 1
TW - Taiwan 1
Totale 108.900
Salva come PNG Salva come JPEG
Città #
Cagliari 100.790
Uta 1.108
Fairfield 549
Woodbridge 426
Chandler 385
Houston 336
Ann Arbor 335
Jacksonville 287
Boardman 271
Ashburn 248
Wilmington 247
Dearborn 222
Nyköping 220
Cambridge 215
Seattle 193
Santa Clara 88
Nanjing 87
Helsinki 65
Shanghai 64
Singapore 63
Boston 62
New York 54
Beijing 50
Nanchang 36
Milan 34
San Diego 32
Shenyang 30
Hebei 27
Jiaxing 27
Verona 26
Guangzhou 23
Hefei 21
Changsha 20
Orange 20
Toronto 17
Auburn Hills 16
Dong Ket 16
Mountain View 16
Redwood City 16
Brussels 13
London 13
Norwalk 13
Tianjin 13
Jinan 12
Kunming 12
Ningbo 11
Los Angeles 10
Washington 10
Rome 9
Ansbach 8
Sassari 8
Taizhou 6
Zhengzhou 6
Perugia 5
Saint Petersburg 5
Atlanta 4
Borås 4
Lahore 4
Wuhan 4
Chengdu 3
Hangzhou 3
Paris 3
Quartu Sant'elena 3
Redmond 3
San Jose 3
Turin 3
Chiswick 2
Columbus 2
Guasila 2
Hounslow 2
Islington 2
Kilburn 2
Murello 2
Naples 2
Phoenix 2
Porto Alegre 2
San Francisco 2
Seoul 2
Southwark 2
Tiantai Chengguanzhen 2
Walnut 2
Wandsworth 2
Wuxi 2
Yiwu 2
Alghero 1
Ambrolauri 1
Amsterdam 1
Aurora 1
Baotou 1
Beaverton 1
Brescia 1
Brooklyn 1
Cairo 1
Cedar Knolls 1
Central District 1
Chicago 1
Concepción 1
Copenhagen 1
Costa Mesa 1
Dallas 1
Totale 106.985
Salva come PNG Salva come JPEG
Nome #
Proteomic investigation of whole saliva in Wilson's disease 4.191
null 3.544
Bipolar disorders and Wilson's disease 3.101
The burden of depressive and bipolar disorders in celiac disease 2.816
Value of histochemical stains for copper in the diagnosis of Wilson's disease 2.633
Coeliac disease and psychiatric comorbidity: epidemiology, pathophysiological mechanisms, quality-of-life, and gluten-free diet effects 2.621
Late onset Wilson's disease 2.452
Premature vascular deterioration in young patients affected by Wilson's disease: a pilot study 2.395
Are prothrombin time and clot waveform analysis useful in detecting a bleeding risk in liver cirrhosis? 2.321
Homogeneous magnetic resonance imaging of brain abnormalities in bipolar spectrum disorders comorbid with Wilson's disease 2.314
Mutation analysis of the ATP7B gene in a new group of Wilson's disease patients: Contribution to diagnosis. 2.266
Brain MRI and SPECT in the diagnosis of early neurological involvement in Wilson's disease 2.241
Clot wave analysis and thromboembolic score in liver cirrhosis: two opposing phenomena 2.172
A Top-Down proteomic study of the whole saliva of subjects affected by Wilson disease reveals qualitative and quantitative alterations of the S100A8 and S100A9 proteins 2.154
Psychiatric comorbidity in Wilson’s disease 2.129
Potential biomarker discover of the Wilson’s disease by top-down proteomic investigation of whole saliva 1.989
Quality of life and psychiatric symptoms in wilson's disease: The relevance of bipolar disorders 1.977
Histologic evolution and long-term outcome of Wilson's disease: results of a single-center experience 1.832
The relationship between copper and steatosis in Wilson's disease 1.777
Add-on peginterferon alfa-2a to nucleos(t)ide analogue therapy for Caucasian patients with hepatitis B 'e' antigen-negative chronic hepatitis B genotype D 1.754
TT virus infection in Italy: prevalence and genotypes in healthy subjects, viral liver diseases and asymptomatic infections by parenterally transmitted viruses 1.750
Fine structure of hepatic sinusoids in Wilson’s disease. A scanning electron microscopic study 1.713
null 1.710
Non-invasive assessment of silent liver fibrosis in patients with systemic sclerosis 1.700
A randomized controlled trial of sequential pegylated interferon-alpha and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B 1.672
Impact of safety-related dose reductions or discontinuations on sustained virologic response in HCV-infected patients: Results from the GUARD-C Cohort 1.635
Reversibility of fibrosis in Wilson disease 1.546
Uneven hepatic copper distribution in Wilson's disease 1.514
Kayser-Fleischer ring in Wilson's disease: a cohort study 1.501
Non-invasive assessment of hepatic fibrosis in a series of patients with Wilson's Disease 1.468
Secondary RBD in a patient affected by chronic hepatic encephalopathy: a case report. 1.406
Brain MR spectroscopy in the evaluation of Wilson's disease: Correlation with clinical status and response to therapy 1.396
HBV and HCV infections in Wilson's disease patients: Copper overload could be protective? 1.396
null 1.366
Dynamic 99mTc-HIDA hepatobiliary scintigraphy in vanishing bile duct syndrome 1.225
Peginterferon-alpha-2a plus adefovir vs. peginterferon alpha-2a for 48 weeks in hbeag-negative chronic hepatitis B: Preliminary 24-week results of the peg for B randomized multicenter trial 1.166
Usefulness of dynamic hepatobiliary scintigraphy in Wilson's disease 1.140
Animal models are reliably mimicking human diseases? A morphological study that compares animal with human NAFLD 1.133
Wilson’s disease with late onset 1.121
Patterns of chronic hepatitis B in Central Italy: a cross-sectional study. 1.091
Tolerability of Peg interferon-alpha 2b and Ribavirin therapy in patients with chronic hepatitis C and glucose-6-phosphate dehydrogenase deficiency 961
HFE gene mutations and Wilson's disease in Sardinia 944
Resolved Psychosis after Liver Transplantation in a Patient with Wilson's Disease 932
Syncitial giant cell hepatitis. A case report 925
Plasma prekallikrein (Fletcher factor) in hepatic cirrhosis 918
Massive haemosiderosis in Wilson’s disease 906
[Short-term effect of treatment with oral DL-carnitine and intravenous L-carnitine in chronic uremia patients undergoing hemodialytic therapy]. FT Effetto a breve termine della terapia con DL-carnitina per os ed L-carnitina e.v. nei pazienti uremici cronici in trattamento emodialitico. 902
A randomized controlled trial of pegylated interferon-alpha 2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B 885
Retrospective, observational, multicentre study on an Italian population affected by chronic hepatitis C who failed to clear HCV-RNA after the combined therapy (PEG-IFN and ribavirin): NADIR study 880
HFE gene mutations and Wilson's disease in Sardinia 878
Short-term effect of treatment with oral DL-carnitine and intravenous L-carnitine in chronic uremia patients undergoing hemodialytic therapy 870
Brain MRI and SPECT in the diagnosis of early neurological involvement in Wilson's disease 869
Massive haemosiderosis in Wilson's disease - Reply 867
SEQUENTIAL PEGINTERFERON ALPHA-2A AND TELBIVUDINE OR VICE VERSA FOR HBEAG-NEGATIVE CHRONIC HEPATITIS B: PRELIMINARY END-OF-TREATMENT RESULTS OF THE TEL-B-PEG RANDOMIZED TRIAL 856
Clinical features of Wilson's disease in Sardinia 803
A randomized controlled trial of amantadine plus interferon-alpha 2a vs. interferon-alpha 2a alone in naive patients with chronic hepatitis C randomized according to the early virological response to interferon-alpha 2a monotherapy 783
Interferon beta-1a alone or in combination with ribavirin: A randomized trial to compare efficacy and safety in chronic hepatitis C 781
Massive hepatic haemosiderosis in Wilson's disease 753
Dosage of the hepatic copper in the normal range in a patient affected by Wilson’s disease. 710
Wilson’s disease with late onset 673
Syncitial giant cell hepatitis: a new form of chronic liver disease 650
Peginterferon alpha-2a (40kD) monotherapy vs peginterferon alpha-2a and ribavirin in naive patients with chronic hepatitis C: Preliminary results of the SMIEC II trial in patients with early viral clearance on peginterferon monotherapy 641
Unusual evolution from overt autoimmune hypothyroidism to hyperthyroidism after IFN-α therapy for chronic hepatitis. 613
Ductular reaction and oval cell prolipheration in chronic hepatitis C. 600
Enhanced response to peginterferon-alpha-2a-based triple therapy in previously non-responsive chronic hepatitis C: Final results of pretty study RID E-8970-2010 589
Epidemiologic study of hepatolenticular degeneration (Wilson's disease) in Sardinia (1902-1983) 570
Chronic viral hepatitis in Hiv + drug addicts 569
Computerized cranial tomography in presymptomatic and hepatic form of Wilson's disease 553
Final results of the SMIEC trial in natve patients with hepatitis C: Double therapy (peginterferonalfa2a+ribavirin) vs peginterferon monotherapy in early viral responders and vs triple therapy (peginterferon plus ribavirin plus amantadine) in early non responders 531
null 520
Comparison of MRI, EEG, EPs and ECD-SPECT in Wilson's disease 518
[Plasma prekallikrein (Fletcher factor) in hepatic cirrhosis]. FT La precallicreina plasmatica (fattore Fletcher) nella cirrosi epatica. 503
Wilson's disease maps between the D13S169 and D13S173 loci 503
HCV transmission in family members of subjects with HCV related chronic liver disease 499
Predictive testing for Wilson's disease using tightly linked and flanking DNA markers 489
alpha 2 Antiplasmin and disseminated intravascular coagulation in liver cirrhosis 482
Diagnostic value of 24 hr urinary copper excretion after penicillamine challenge in the adult Wilson's disease patients. 464
Coagulazione, fibrinolisi e shunt porto-sistemico nelle epatopatie croniche 448
IS INTRAPULMONARY SHUNT IN CIRRHOTIC-PATIENTS CORRELATED WITH PORTACAVAL-SHUNT 436
HDL-cholesterol in chronic uremia during hemodialytic treatment 436
A randomized controlled trial of amantadine plus interferon alpha-2a vs interferon-alpha-2a in naive patients with chronic hepatitis C randomized based on early response to interferon alpha-2a alone. 417
Idiopathic adulthood ductopenia presenting with chronic recurrent cholestasis. A case report 407
Pseudo-porphyria cutanea tarda in patients hemodialyzed for chronic renal insufficiency. Clinical, metabolic and immunological aspect 396
Usefulness and limitations of determination of lactate dehydrogenase enzymes in the diagnosis of liver diseases 383
Hypothalamo-pituitary-adrenal function in liver cirrhosis of viral etilogy 339
The role of a double liver needle biopsy in the diagnosis of Wilson's disease. 324
Transient elastography in patients with chronic autoimmune hepatitis: is a goog tool in evaluation of hepatic fibrosis? 317
ABNORMAL PULMONARY EPITHELIAL PERMEABILITY IN LIVER-CIRRHOSIS 315
Diagnostic value of histochemical stains for copper in Wilson's disease 305
Efficacy and safety of long-term IFN therapy in active chronic hepatitis D: Six years of sustained response to the treatment. Case report. 291
Efficacy of lamivudine in patients with antiHBe plus chronic active hepatitis B. 289
Serum ALT level, phlebotomy treatment and alpha-interferon therapy in chronic hepatitis C. 224
Totale 109.045
Salva come PNG Salva come JPEG
Categoria #
all - tutte 132.931
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 132.931
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202019.156 0 0 0 0 8.018 5.484 2.867 678 396 374 426 913
2020/202126.940 807 1.072 1.118 7.236 5.636 3.298 2.232 1.657 514 1.476 1.124 770
2021/20227.452 652 615 443 495 513 825 601 319 419 514 902 1.154
2022/20238.388 993 1.192 1.086 737 831 914 320 665 385 416 485 364
2023/20247.300 491 421 320 788 762 1.091 953 480 343 536 588 527
2024/20256.763 2.045 2.139 1.148 944 487 0 0 0 0 0 0 0
Totale 109.045